Abstracts on line are sponsored by
Poster Presentations
31 March - 2, April, 2011
Poster Board Number
Category 15: Late-Breakers:
| IL28B POLYMORPHISMS LINKED TO POOR RESPONSE TO TREATMENT ARE ASSOCIATED WITH LOW NECROINFLAMMATORY ACTIVITY AND SLOW FIBROSIS PROGRESSION IN HCV GENOTYPE NON-1-INFECTED PATIENTS P.-Y. Bochud1*, S. Bibert2, Z. Kutalik3,4, N. Goossens5, B. Müllhaupt6, T. Gerlach7, M. Heim8, D. Moradpour9, A. Cerny10, R. Malinverni11, J.-F. Dufour12, F. Negro5, The Swiss Hepatitis C Cohort Study Group 1Infectious Diseases, 2University Hospital of Lausanne, 3University of Lausanne, 4Swiss Institute of Bioinformatics, Lausanne, 5University Hospital of Geneva, Geneva, 6University Hospital of Zurich, Zurich, 7Canton Hospital, St Gallen, 8University Hospital, Basel, 9University Hospital, Lausanne, 10Clinica Moncucco, Lugano, 11Hôpital Pourtalès, Neuchatel, 12University Hospital, Berne, Switzerland. *pierre-yves.bochud@chuv.ch | 1361 |
| THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION S. Deuffic-Burban1,2*, P. Mathurin3,4, S. Pol5, C. Larsen6, F. Roudot-Thoraval7, J.-C. Desenclos6, D. Dhumeaux8, Y. Yazdanpanah1,2,9 1ATIP-AVENIR, Inserm U995, Université Lille Nord de France, Loos, 2EA2694, Université Lille Nord de France, 3Service des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital Huriez, CHRU Lille, 4Inserm U995, Université Lille Nord de France, Lille, 5Groupe Hospitalier Cochin Hôtel Dieu, Unité d'Hépatologie, Université Paris Descartes et Inserm U-1016, Paris, 6Département des maladies infectieuses, Institut de Veille Sanitaire, Saint Maurice, 7Service Santé Publique, Hôpital Henri Mondor, 8Inserm U955, Physiopathologie et thérapeutique des hépatites virales chroniques, Hôpital Henri-Mondor, Créteil, 9Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France. *sylvie.burban@neuf.fr | 1362 |
| VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS A.M. Di Bisceglie1*, D.R. Nelson2, E. Gane3, K. Alves4, M.J. Koziel4, C. De Souza4, T.L. Kieffer4, S. George4, R.S. Kauffman4, I.M. Jacobson5, M.S. Sulkowski6, ZENITH Study Team 1St Louis University School of Medicine, St. Louis, MO, 2University of Florida College of Medicine, Gainesville, FL, USA, 3Auckland City Hospital, Auckland, New Zealand, 4Vertex Pharmaceuticals Incorporated, Cambridge, MA, 5Weill Cornell Medical College, New York, NY, 6Johns Hopkins University, Baltimore, MD, USA. *dibiscam@slu.edu | 1363 |
| DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY J. Dietz1*, U. Mihm1, S.-E. Schelhorn2, D. Fitting1, S. Susser1, T. Lengauer2, S. Zeuzem1, E. Herrmann1, C. Sarrazin1 1Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität, Frankfurt/Main, 2Max-Planck-Institut für Informatik, Saarbrücken, Germany. *julia.dietz@em.uni-frankfurt.de | 1364 |
| ACUTE KIDNEY INJURY NETWORK (AKIN) CRITERIA FOR ACUTE RENAL FAILURE PREDICTS OUTCOME IN HOSPITALIZED CIRRHOTIC PATIENTS. A PROSPECTIVE STUDY C. Fagundes1,2,3*, M. Guevara1,2,3, E. García-López1,2,3, G.H. Pereira1,2,3, E. Solà1,2,3, E. Rodríguez1,2,3, M. Pavesi1,2,3, V. Arroyo1,2,3, P. Ginès1,2,3 1Liver Unit, University of Barcelona, 2IDIBAPS, 3CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. *cgoncalv@clinic.ub.es | 1365 |
| HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN S. Flamm1*, E. Lawitz2, I. Jacobson3, R. Rubin4, M. Bourliere5, C. Hezode6, J. Vierling7, C. Niederau8, M. Sherman9, V. Goteti10, R. Vilchez10, C. Brass10, J. Albrecht10, F. Poordad11 1Northwestern Feinberg School of Medicine, Chicago, IL, 2Alamo Medical Research, SanAntonio, TX, 3Weill Cornell Medical College, New York, NY, 4Liver Center of Atlanta, Atlanta, GA, USA, 5Fondation Hopital Saint Joseph, Marseille, 6A.P.H. Paris, Hopital Henri Mondor, Creteil Cedex, France, 7Baylor College of Medicine, Houston, TX, USA, 8St. Josef-Hospital Oberhausen, Oberhausen, Germany, 9Toronto General Hospital, Toronto, ON, Canada, 10Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 11Cedars-Sinai Medical Center, Los Angeles, CA, USA. *s-flamm@northwestern.edu | 1366 |
| RELAPSE AFTER ANALOGUES TREATMENT DISCONTINUATION IS NOT PREVENTED BY DNA VACCINATION IN CHRONIC HEPATITIS B (ANRS HB 02 VAC-ADN) H. Fontaine1,2*, C. Chazallon3, M. Mancini-Bourgine4,5, P. Lebray6, C. Buffet7, S. Kahi8, O. Godon9, J.-F. Meritet10, Y. Saïdi11, M.-L. Michel12,13, D. Scott-Algara14, J.-P. Aboulker15, S. Pol16,17,18, ANRS HB 02 VAC-ADN Study Group 1Unité d'Hepatologie, APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, 2CNRS (UMR 8104), Institut Cochin, Université Paris Descartes (UMR S1016), Paris, 3SC10, INSERM, Villejuif, 4Laboratoire de pathogenèse des virus de l'hépatite B, Institut Pasteur, 5U845, Institut national de la santé et de la recherche médicale, 6Hepatology Unit, Hôpital de la Pitié-Salpétrière, Paris, 7Hepatology Unit, Hôpital du Kremlin-Bicêtre, Le Kremlin-Bicêtre, 8SC10, InNSERM, Villejuif, 9laboratoire de pathogenèse des virus de l'hépatite B, Institut Pasteur, 10Virology Unit, APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, Paris, 11SC10, Inserm, Villejuif, 12Laboratoire de pathogénèse des virus de l'hépatite B, Institut Pasteur, 13U845, Institut de la Santé et de la Recherche Biomédicale, 14Unité de régulation des infections rétrovirales, Institut Pasteur, 15SC10, Inserm, 16Unité d'Hépatologie, Groupe Hospitalier Cochin Saint-Vincent de Paul, 17UMR S1016, Institut Cochin, Université Paris Descartes, 18U1016, Inserm, Paris, France. *helene.fontaine@cch.aphp.fr | 1367 |
| WESTERN TRIAL COMPARING PERCUTANEOUS RADIOFREQUENCY OF BOTH HEPATOCELLULAR CARCINOMA AND THE PORTAL VENOUS TUMOR THROMBUS PLUS SORAFENIB WITH SORAFENIB ALONE A. Giorgio*, N. Farella, A. di Sarno, U. Scognamiglio, G. de Stefano, A. de Rogatis, E. Trapenese, V. Giorgio Infectious Disease and Interventional Ultrasound Unit, Naples, Italy. *assanui1@virgilio.it | 1368 |
| TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL I.M. Jacobson1*, I. Catlett2, P. Marcellin3, N.H. Bzowej4, A.J. Muir5, N. Adda2, L. Bengtsson2, S. George2, S. Seepersaud2, R. Ramachandran2, K. Sussky2, R.S. Kauffman2, M. Botfield2 1Weill Cornell Medical College, New York, NY, 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 3Hôpital Beaujon, Clichy, France, 4California Pacific Medical Center, San Francisco, CA, 5Duke University Medical Center, Durham, NC, USA. *imj2001@med.cornell.edu | 1369 |
| ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) E. Lawitz1*, M. Rodriguez-Torres2, J. Denning3, M. Cornpropst3, D. Clemons3, L. Mcnair3, M.M. Berrey3, W. Symonds3 1Alamo Medical Resarch, San Antonio, TX, 2Fundacion de Investigacion De Diego, San Juan, PR, 3Pharmasset, Inc., Princeton, NJ, USA. *lawitz@alamomedicalresearch.com | 1370 |
| PROGRESS TOWARD THE CLINICAL APPLICATION OF AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS AND GENE REPAIR THERAPY FOR TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA A. Bosman1, B.E. Wildhaber2, J. Birraux2, C. Jond2, M. Jaconi1, O. Menzel2* 1Dpt. of Pathology and Immunology, 2Research Laboratory of Pediatric Surgery (Dpt. of Pathology and Immunology), University of Geneva Medical School (CMU), Geneva, Switzerland. *olivier.menzel@unige.ch | 1371 |
| ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY D.R. Nelson1*, J. Lalezari2, E. Lawitz3, T. Hassanein4, K. Kowdley5, F. Poordad6, A. Sheikh7, N. Afdhal8, D. Bernstein9, E. Dejesus10, B. Freilich11, D. Dieterich12, I. Jacobson13, D. Jensen14, G.A. Abrams15, J. Darling16, M. Rodriguez-Torres17, R. Reddy18, M. Sulkowski19, N. Bzowej20, M. Demicco21, J. Strohecker22, R. Hyland23, M. Mader23, E. Albanis23, W.T. Symonds23, M.M. Berrey23 1University of Florida, Gainesville, FL, 2Quest Clinical Research, San Francisco, CA, 3Alamo Medical Research, Ltd, San Antonio, TX, 4University of California, San Diego, Coronado, CA, 5Virginia Mason Medical Center, Seattle, WA, 6Cedars-Sinai Medical Center, Los Angeles, CA, 7GI Specialists of Georgia, Marietta, GA, 8Beth Israel Deaconess Medical Center,Harvard Medical School, Boston, MA, 9Digestive Diseases Institute of the Division of Gastroenterology, Hepatology, and Nutrition, Manhasset, NY, 10Orlando Immunology Center, Orlando, FL, 11Kansas City Gastroenterology & Hepatology, LLCG, Kansas City, KS, 12Mount Sinai School of Medicine, New York, 13Cornell University, New York, NY, 14University of Chicago Hospital, Chicago, IL, 15Alabama Liver and Digestive Specialists, Montgomery, AL, 16University of North Carolina at Chapel Hill, Chapel Hill, NC, 17Fundacion de Investigacion De Diego, Santurce, PR, 18University of Pennsylvania Health System, Philadelphia, PA, 19Johns Hopkins University School of Medicine, Lutherville, MD, 20California Pacific Medical Center, San Francisco, 21Advanced Clinical Research Institute, Anaheim, CA, 22Columbia Gastroenterology, Columbia, SC, 23Pharmasset, Inc, Princeton, NJ, USA. *david.nelson@medicine.ufl.edu | 1372 |
| FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR, BMS-790052 IN COMBINATION WITH PEG-IFNα-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS S. Pol1*, R.H. Ghalib2, V.K. Rustgi3, C. Martorell4, G.T. Everson5, H.A. Tatum6, C. Hezode7, J.K. Lim8, J.-P. Bronowicki9, G.A. Abrams10, N. Brau11, D.W. Morris12, P. Thuluvath13, R. Reindollar14, P.D. Yin15, U. Diva15, R. Hindes15, F. McPhee15, M. Gao15, A. Thiry15, S. Schnittman15, E.A. Hughes15 1Hôpital Cochin, Paris, France, 2Liver Institute at Methodist Health System, Dallas, TX, 3Metropolitan Research, Fairfax, VA, 4The Research Institute, Springfield, MA, 5University of Colorado, Aurora, CO, 6Options Health Research, LLC, Tulsa, OK, USA, 7CHU Henri Mondor, CRETEIL, France, 8Yale University School of Medicine, New Haven, CT, USA, 9Hopitale Adultes de Braboios, Vandoeuvre les Nancy, France, 10Alabama Liver & Digestive Specialists, Montgomery, AL, 11James J Peters VAMC, Bronx, NY, 12Healthcare Research Consultants, Tulsa, OK, 13Mercy Medical Center, Baltimore, MD, 14Carolinas Center for Liver Disease Research Dept, Statesville, NC, 15Bristol Meyer Squibb Co., Wallingford, CT, USA. *stanislas.pol@cch.aphp.fr | 1373 |
| LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES Z. Stamataki1*, O.S. Qureshi1, G.M. Reynolds2, C. Mee1, P. Maurel3, L. Hibbert4, J.A. Waters4, G.R. Foster4, J.Z. Rappoport5, S.G. Hübscher6, D.H. Adams2, J.A. McKeating1 1MRC Centre for Immune Regulation, University of Birmingham, 2Centre for Liver Research, NIHR Biomedical Research Unit, University of Birmingham, Birmingham, UK, 3Hepatic Stem Cells and Liver Biotherapy, Inserm U1040, IRB, CHRU Saint Eloi, Montpellier, France, 4The Liver Unit, Queen Mary University of London, London, 5School of Biosciences, University of Birmingham, 6Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. *z.stamataki@bham.ac.uk | 1374 |
| SPLEEN STIFFNESS MEASUREMENT USING FIBROSCAN AND A MODIFIED CALCULATION ALGORITHM INCREASES THE DIAGNOSIS PERFORMANCE OF LARGE ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS H. Stefanescu1*, C. Bastard2, M. Lupsor1, D. Feier1, V. Miette2, L. Sandrin2, R. Badea1 13rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, 2Echosens, Paris, France. *hstefanescu@umfcluj.ro | 1375 |
| THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT S. Zeuzem1*, G.R. Foster2, M.W. Fried3, C. Hezode4, G.M. Hirschfield5, I. Nikitin6, F. Poordad7, O. Lenz8, M. Peeters8, V. Sekar9, G. De Smedt8 1J.W. Goethe University Hospital, Frankfurt, Germany, 2Queen Marys University of London, London, UK, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Hôpital Henri-Mondor, Université Paris-Est Créteil, Créteil, France, 5Toronto Western Hospital Liver Centre, Toronto, ON, Canada, 6Russian State Medical University, Moscow, Russia, 7Cedars-Sinai Medical Center, Los Angeles, CA, USA, 8Tibotec BVBA, Mechelen, Belgium, 9Tibotec Inc, Yardley, PA, USA. *zeuzem@em.uni-frankfurt.de | 1376 |